Viking Therapeutics Stock Buy Hold or Sell Recommendation
| VKTX Stock | USD 30.89 1.16 3.90% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Viking Therapeutics is 'Cautious Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Viking Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Viking Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Viking Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide. In addition, we conduct extensive research on individual companies such as Viking and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Viking Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Viking |
Execute Viking Therapeutics Buy or Sell Advice
The Viking recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Viking Therapeutics. Macroaxis does not own or have any residual interests in Viking Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Viking Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Viking Therapeutics Trading Alerts and Improvement Suggestions
| Viking Therapeutics generated a negative expected return over the last 90 days | |
| Viking Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (109.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Viking Therapeutics currently holds about 155.02 M in cash with (87.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.02. | |
| Viking Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from zacks.com: Viking Therapeutics, Inc. Ascends While Market Falls Some Facts to Note |
Viking Therapeutics Returns Distribution Density
The distribution of Viking Therapeutics' historical returns is an attempt to chart the uncertainty of Viking Therapeutics' future price movements. The chart of the probability distribution of Viking Therapeutics daily returns describes the distribution of returns around its average expected value. We use Viking Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Viking Therapeutics returns is essential to provide solid investment advice for Viking Therapeutics.
| Mean Return | -0.62 | Value At Risk | -10.98 | Potential Upside | 8.39 | Standard Deviation | 5.16 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Viking Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Viking Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Viking Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Viking Therapeutics back and forth among themselves.
| Shares | Norges Bank | 2024-12-31 | 1.3 M | Pictet Asset Manangement Sa | 2024-12-31 | 1.2 M | Alliancebernstein L.p. | 2024-12-31 | 1.1 M | Susquehanna International Group, Llp | 2024-12-31 | 1 M | International Assets Investment Management, Llc | 2024-09-30 | 1 M | Perceptive Advisors Llc | 2024-12-31 | 995.9 K | Amvescap Plc. | 2024-12-31 | 872.8 K | Balyasny Asset Management Llc | 2024-12-31 | 860.4 K | Charles Schwab Investment Management Inc | 2024-12-31 | 728.7 K | Fmr Inc | 2024-12-31 | 16.7 M | Vanguard Group Inc | 2024-12-31 | 10.2 M |
Viking Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Free Cash Flow | (21.8M) | (47.6M) | (48.4M) | (73.4M) | (87.8M) | (83.4M) | |
| Other Non Cash Items | 138K | 29K | 1.3M | (8.1M) | 272K | 423.6K | |
| Net Income | (39.5M) | (55.0M) | (68.9M) | (85.9M) | (110.0M) | (104.5M) | |
| Change In Cash | 20.7M | (2.7M) | 10.3M | 18.9M | (28.8M) | (27.4M) | |
| End Period Cash Flow | 29.1M | 26.4M | 36.6M | 55.5M | 26.7M | 20.3M | |
| Investments | 41.6M | 38.0M | 54.8M | (207.6M) | (553.4M) | (525.7M) | |
| Depreciation | 277K | 296K | 291K | 292K | (17.2M) | (16.3M) | |
| Change To Netincome | 3.7M | 5.8M | 6.1M | 8.7M | 10.0M | 10.5M |
Viking Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Viking Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Viking Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Viking stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.55 | |
β | Beta against Dow Jones | 0.68 | |
σ | Overall volatility | 5.31 | |
Ir | Information ratio | -0.1 |
Viking Therapeutics Volatility Alert
Viking Therapeutics exhibits very low volatility with skewness of -0.66 and kurtosis of 2.24. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Viking Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Viking Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Viking Therapeutics Implied Volatility
Viking Therapeutics' implied volatility exposes the market's sentiment of Viking Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Viking Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Viking Therapeutics stock will not fluctuate a lot when Viking Therapeutics' options are near their expiration.
Viking Therapeutics Fundamentals Vs Peers
Comparing Viking Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Viking Therapeutics' direct or indirect competition across all of the common fundamentals between Viking Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Viking Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Viking Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Viking Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Viking Therapeutics to competition |
| Fundamentals | Viking Therapeutics | Peer Average |
| Return On Equity | -0.18 | -0.31 |
| Return On Asset | -0.15 | -0.14 |
| Current Valuation | 2.56 B | 16.62 B |
| Shares Outstanding | 112.25 M | 571.82 M |
| Shares Owned By Insiders | 2.00 % | 10.09 % |
| Shares Owned By Institutions | 74.22 % | 39.21 % |
| Number Of Shares Shorted | 25.11 M | 4.71 M |
| Price To Earning | (3.17) X | 28.72 X |
| Price To Book | 3.94 X | 9.51 X |
| EBITDA | (150.92 M) | 3.9 B |
| Net Income | (109.96 M) | 570.98 M |
| Cash And Equivalents | 155.02 M | 2.7 B |
| Cash Per Share | 2.02 X | 5.01 X |
| Total Debt | 1.12 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 11.74 X | 2.16 X |
| Book Value Per Share | 7.89 X | 1.93 K |
| Cash Flow From Operations | (87.79 M) | 971.22 M |
| Short Ratio | 4.71 X | 4.00 X |
| Earnings Per Share | (1.01) X | 3.12 X |
| Price To Earnings To Growth | (0.03) X | 4.89 X |
| Target Price | 99.29 | |
| Number Of Employees | 36 | 18.84 K |
| Beta | 0.9 | -0.15 |
| Market Capitalization | 3.47 B | 19.03 B |
| Total Asset | 908.32 M | 29.47 B |
| Retained Earnings | (487.91 M) | 9.33 B |
| Working Capital | 879.8 M | 1.48 B |
| Current Asset | 15.2 M | 9.34 B |
| Current Liabilities | 1.98 M | 7.9 B |
| Net Asset | 908.32 M |
Note: Disposition of 35000 shares by Brian Lian of Viking Therapeutics at 23.95 subject to Rule 16b-3 [view details]
Viking Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Viking . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Viking Therapeutics Buy or Sell Advice
When is the right time to buy or sell Viking Therapeutics? Buying financial instruments such as Viking Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Viking Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Municipals ETFs Thematic Idea Now
Municipals ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Municipals ETFs theme has 116 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Municipals ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Viking Stock Analysis
When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.